Heranba Industries Limited · NSE:HERANBA
Heranba Industries — Q4 FY23 Earnings Presentation
28 slides from Heranba Industries's earnings presentation, May 2023
Slide 1: Investor Presentation Q4FY23
Investor Presentation Q4FY23 || May 2023 BSE: 543266 | NSE: HERANBA | ISIN: INE694N01015 www.heranba.co.in
Slide 2: Safe Harbor
Safe This presentation and the accompanying slides (the “Presentation”), which have been prepared by Heranba Industries Harbor Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 3: Contents
Contents Company Overview 01 SLIDE 04 Management Team 02 SLIDE 11 Quarterly Performance 03 SLIDE 13 Financial Performance 04 SLIDE 18 Strategy for Growth 05 SLIDE 25
Slide 4: Company Overview
Section: 01 Company Overview Heranba at glance Our journey Value chain SLIDE 05 SLIDE 06 SLIDE 07 Intermediaries Technicals Formulations SLIDE 08 SLIDE 09 SLIDE 10
Slide 5: Heranba at a Glance
Heranba at a Glance 60+ 4 65+ 850+ Revenue from Institutional Manufacturing Countries Employees customers** Facilities Presence (as of FY23) (as of FY23) 8500+ 41% ~20% Dealers Revenue from Revenue from 14.4% Exports as % of sales Top 10 customers ROE# across India (as of FY23) (as of FY23) (as of F
Slide 6: Our Journey
Our Journey FORMULATIONS Forward integrated into the manufacturing ISO CERTIFICATE of Formulations developed from Company’s Receipt of ISO 9001:2015 synthetic pyrethroids product portfolio of certification in respect of production EXPORTS CMAC cypermethrin, alphacypermethrin, & dispatch of agro Form
Slide 7: Value Chain
Value Chain Manufacturing Process The process of manufacturing HIL manufactures a wide range of products, and each product has its can be classified broadly into own unique manufacturing process three stages Value Chain The Company specializes in the manufacturing processes that mainly include
Slide 8: Intermediaries
Intermediaries Cypermethric Acid Chloride (CMAC) End-use High CIS CMA High Trans CMA Intermediates manufactured are for Company’s own captive consumption for manufacturing various Technicals and Formulations Metaphenoxy High Trans CMAC Bromobenzenes Benzaldehyde (MPBD)
Slide 9: Technicals
Technicals Herbicides Glyphosate Metribuzin Insecticides Clodinofop Cypermethrin Deltamethrin Alpha Cypermethrin Acephate Lambda Cyhalothrin Permethrin Technicals Profenophos Temephos Theta Cypermethrin Thiamethoxam Imidacloprid Fungicides Tricyclazole Hexaconazole
Slide 10: Formulations
Formulations Revenue from Technical and Formulations Herbicides (₹ in Million) Glory Glory 71 Chakde Shera Insecticides Heraquat Pendant Jayam Zinta Atria Progress Plus Param Cypraplus 9,669 Dyken 8,570 Formulations 7,628 Mantra 7,280 6,481 Astron 5,540 4,971 4,677 Si
Slide 11: Management
An ISO 9001:2015 Company (@) HERANBA INDUSTRIES LIMITED Section: 02 Management
Slide 12: Experienced Promoters with Domain Knowledge
Experienced Promoters with Domain Knowledge Promoters having a cumulative experience of more than six decades Mr. Sadashiv K. Shetty Mr. Raghuram K. Shetty Chairman and Executive Director Managing Director Holds a bachelor’s (physics and chemistry) and master’s (chemistry) Holds a bachelor’s deg
Slide 13: Quarterly Performance
Section: 03 Quarterly Performance Management Quarterly P&L Summary Commentary Performance SLIDE 16 & 17 SLIDE 14 SLIDE 15
Slide 14: FY23 Management Commentary
FY23 Management Commentary Mr. Raghuram K. Shetty, Managing Director of Heranba Industries Limited, commented, “The Company’s FY23 revenues stood at ₹13,380 million restricted by unfavourable global economic scenario, inventory build-up in the system and sluggish demand from key export regions. Howe
Slide 15: Quarterly Performance (Standalone)
Quarterly Performance (Standalone) Net Revenue from EBITDA(incl. Other Rev) PAT and PAT Margin Business Mix Operations and EBITDA Margin (₹ IN MILLION & %) (IN %) (₹ IN MILLION) (IN ₹ MILLION & %) 19.0% 4,000 13% 12.2% 20% 21% 10.3% 3,500 9.4% 5.5% 5.1% 3,000 22% 22% 2,500 31% 32% 2,000 1,500 36% 31
Slide 16: Profit & Loss Summary (Standalone)
Profit & Loss Summary (Standalone) (Quarterly) Figures in ₹ Million, except EPS and Margins PARTICULARS Q4FY22 Q3FY23 Q4FY23 Revenue from Operations 3,501 2,802 2,589 Other Income 48 9 43 Total Revenue 3,549 2,811 2,632 Total Expenses 2,967 2,627 2,450 Profit Before Tax 583 184 182 Total Tax Expense
Slide 17: Profit & Loss Summary (Consolidated)
Profit & Loss Summary (Consolidated) (Quarterly) Figures in ₹ Million, except EPS and Margins PARTICULARS Q1FY23 Q2FY23 Q3FY23 Q4FY23 Revenue from Operations 3,619 4,207 2,760 2,602 Other Income 44 40 6 31 Total Revenue 3,664 4,247 2,767 2,633 Total Expenses 3,221 3,621 2,603 2,487 Profit Before Tax
Slide 18: Financial Performance
Section: 04 Financial Performance Key Ratios Financial Summary SLIDE 19 SLIDE 21
Slide 19: Key Financial Metrics (Standalone)
Key Financial Metrics (Standalone) Net Revenue EBITDA(incl. Other Rev) PAT and Net Debt/(Cash) from Operations and EBITDA Margin PAT Margin and Equity (₹ IN MILLION) (IN ₹ MILLION & %) (₹ IN MILLION & %) (₹ IN MILLION) 13.0% 12.7% 18.6% 19.0% 10.3% (296.2) 8.3% 7.5% 15.1% 13.7% 13.1% (336.0) (345.0)
Slide 20: Standalone Business Mix
Standalone Business Mix Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market Revenue from Operations Revenue from Domestic / Exports (IN%) (% OF SALES) Export Revenue Split: Technical and Formulations Export 32% 28% 36% 41% 39%
Slide 21: Profit & Loss Summary (Standalone)
Profit & Loss Summary (Standalone) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 FY23 Revenue from Operations 10,044.4 9,513.7 12,186.5 14,503.7 13,243.8 Other Income 73.9 165.3 70.3 193.5 135.8 Total Revenue 10,118.4 9,679.1 12,256.8 14,697.2 13,379.6 Total Expenses 8,897.2 8,390.6 10,173.9 12,144
Slide 22: Standalone Balance Sheet (1/2)
Standalone Balance Sheet (1/2) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 FY23 Non-Current Assets Property, plant and equipment 511.4 954.4 1,334.4 1,934.2 1,859.9 Capital work-in-progress 159.7 377.7 97.0 142.3 420.4 Financial Assets: (i) Investments 0.2 37.3 101.0 21.3 9.2 (ii) Loans 531.9 (ii
Slide 23: Standalone Balance Sheet (2/2)
Standalone Balance Sheet (2/2) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 FY23 Equity and liabilities Equity Equity share capital 390.6 390.6 400.1 400.1 400.1 Other equity 1,891.2 2,817.9 4,881.2 6,744.4 7,761.0 Total Equity 2,281.8 3,208.5 5,281.3 7,144.5 8,161.1 Liabilities Non-Current Liabil
Slide 24: Standalone Cashflow Statement
Standalone Cashflow Statement (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 FY22 FY23 Cash Flow from Operations 877.02 542.11 603.98 981.1 1,225.0 Cash Flow from Investing Activities -373.79 -520.39 -407.13 -817.2 -1,000.6 Cash Flow from financing Activities -411.35 -199.43 619.01 -62.7 -180.8 Net incre
Slide 25: Strategy for growth
Section: 05 Strategy for growth Competetive Strengths Business Strategy SLIDE 26 SLIDE 27
Slide 26: Competitive Strengths
Competitive Strengths Experienced Promoters and Management Team Wide Distribution Wide range of products Network across value chain Integrated Diversified Manufacturing Units Customer Base Exports to more Product Registration than 60 countries enabling global outreach
Slide 27: Business Strategy
Business Strategy Well positioned to exploit opportunities offered by growth in Agrochemicals Entering Highly Strengthening of Enhancing Enhancing Branded Regulated USA and R&D Facility Production Formulation Formulations and Europe markets Capabilities & Technicals in Public Health International Ma
Slide 28: Thank You
Corporate Office Investor Relations Contacts: Heranba Industries Ltd. Hiral Keniya 2nd Floor, A Wing, ✉hiral.keniya@in.ey.com Fortune Avirahi, Jain Derasar Lane , Vikash Verma Borivali (W), ✉ vikash.verma1@in.ey.com Mumbai – 400 092, India Tel : 91-22-2898 7912/14, 91-22-2898 2133/44, Thank You 91-2